| Record Information | 
|---|
| Version | 5.0 | 
|---|
| Status | Expected but not Quantified | 
|---|
| Creation Date | 2012-09-06 15:16:52 UTC | 
|---|
| Update Date | 2022-03-07 02:52:00 UTC | 
|---|
| HMDB ID | HMDB0015474 | 
|---|
| Secondary Accession Numbers |  | 
|---|
| Metabolite Identification | 
|---|
| Common Name | Methotrimeprazine | 
|---|
| Description | Methotrimeprazine, also known as levomepromazine or tisercin, belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. As is typical of phenothiazine antipsychotics, levomepromazine is a "dirty drug", that is, it exerts its effects by blocking a variety of receptors, including adrenergic receptors, dopamine receptors, histamine receptors, muscarinic acetylcholine receptors and serotonin receptors. Methotrimeprazine is a drug which is used for the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder. Levomepromazine is frequently prescribed and valued worldwide in palliative care medicine for its multimodal action, to treat intractable nausea or vomiting, and for severe delirium/agitation in the last days of life. Methotrimeprazine is a very strong basic compound (based on its pKa). Methotrimeprazine is a potentially toxic compound. Serious side effects include tardive dyskinesia, akathisia, abnormalities in the electrical cycle of the heart, low blood pressure and the potentially fatal neuroleptic malignant syndrome. Brand names include Nozinan, Levoprome, Detenler, Hirnamin, Levotomin and Neurocil. Palliative care physicians will commonly prescribe it orally or via subcutaneous syringe drivers in combination with opioid analgesics such as hydromorphone. A 2010 systematic review compared the efficacy of levomepromazine with atypical antipsychotic drugs:The most common side effect is akathisia. Levomepromazine is used for the treatment of psychosis, particularly those of schizophrenia, and manic phases of bipolar disorder. In any case, blood pressure and EKG should be monitored regularly. A rare but life-threatening side effect is neuroleptic malignant syndrome (NMS). | 
|---|
| Structure | COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1 | 
|---|
| Synonyms | | Value | Source | 
|---|
 | (-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine | ChEBI |  | (-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine | ChEBI |  | 2-Methoxytrimeprazine | ChEBI |  | Levomepromazina | ChEBI |  | Levomepromazine | ChEBI |  | Levomepromazinum | ChEBI |  | Levoprome | Kegg |  | Levopromazine | HMDB |  | Tisercin | HMDB |  | Levomeprazin | HMDB |  | Tizertsin | HMDB |  | Tizercine | HMDB | 
 | 
|---|
| Chemical Formula | C19H24N2OS | 
|---|
| Average Molecular Weight | 328.472 | 
|---|
| Monoisotopic Molecular Weight | 328.16093409 | 
|---|
| IUPAC Name | [(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine | 
|---|
| Traditional Name | methotrimeprazine | 
|---|
| CAS Registry Number | 60-99-1 | 
|---|
| SMILES | COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1 | 
|---|
| InChI Identifier | InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1 | 
|---|
| InChI Key | VRQVVMDWGGWHTJ-CQSZACIVSA-N | 
|---|
| Chemical Taxonomy | 
|---|
| Description | Belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. | 
|---|
| Kingdom | Organic compounds | 
|---|
| Super Class | Organoheterocyclic compounds | 
|---|
| Class | Benzothiazines | 
|---|
| Sub Class | Phenothiazines | 
|---|
| Direct Parent | Phenothiazines | 
|---|
| Alternative Parents |  | 
|---|
| Substituents | PhenothiazineAlkyldiarylamineDiarylthioetherAryl thioetherAnisoleTertiary aliphatic/aromatic amineAlkyl aryl etherPara-thiazineBenzenoidTertiary aliphatic amineTertiary amineEtherAzacycleThioetherOrganooxygen compoundOrganonitrogen compoundOrganic nitrogen compoundOrganopnictogen compoundHydrocarbon derivativeOrganic oxygen compoundAmineAromatic heteropolycyclic compound
 | 
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds | 
|---|
| External Descriptors |  | 
|---|
| Ontology | 
|---|
| Physiological effect | Not Available | 
|---|
| Disposition |  | 
|---|
| Process | Not Available | 
|---|
| Role |  | 
|---|
| Physical Properties | 
|---|
| State | Solid | 
|---|
| Experimental Molecular Properties | | Property | Value | Reference | 
|---|
 | Melting Point | Not Available | Not Available |  | Boiling Point | Not Available | Not Available |  | Water Solubility | 0.0052 g/L | Not Available |  | LogP | 4.68 | HANSCH,C ET AL. (1995) | 
 | 
|---|
| Experimental Chromatographic Properties | Not Available | 
|---|
| Predicted Molecular Properties |  | 
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference | 
|---|
 | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.92 minutes | 32390414 |  | Predicted by Siyang on May 30, 2022 | 11.3912 minutes | 33406817 |  | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.87 minutes | 32390414 |  | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 45.1 seconds | 40023050 |  | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1374.7 seconds | 40023050 |  | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 231.2 seconds | 40023050 |  | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 177.5 seconds | 40023050 |  | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 185.2 seconds | 40023050 |  | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 107.4 seconds | 40023050 |  | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 408.1 seconds | 40023050 |  | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 489.6 seconds | 40023050 |  | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 553.0 seconds | 40023050 |  | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 984.8 seconds | 40023050 |  | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 343.2 seconds | 40023050 |  | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1146.6 seconds | 40023050 |  | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 237.4 seconds | 40023050 |  | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 375.9 seconds | 40023050 |  | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 322.5 seconds | 40023050 |  | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 391.5 seconds | 40023050 |  | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.8 seconds | 40023050 | 
 Predicted Kovats Retention IndicesUnderivatized | 
|---|
|  | GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View | 
|---|
 | Predicted GC-MS | Predicted GC-MS Spectrum - Methotrimeprazine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-9272000000-663ed1e564555c7e8fae | 2017-09-01 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Methotrimeprazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Methotrimeprazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |  | MS | Mass Spectrum (Electron Ionization) | splash10-056r-9356000000-bb17e4980980d336d337 | 2014-09-20 | Not Available | View Spectrum | 
 MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View | 
|---|
 | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methotrimeprazine LC-ESI-QQ , positive-QTOF | splash10-004i-0009000000-292add600a1d733c3662 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methotrimeprazine LC-ESI-QQ , positive-QTOF | splash10-004i-0319000000-9bcdb870e16f29c42cc7 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methotrimeprazine LC-ESI-QQ , positive-QTOF | splash10-0udi-2920000000-f73fff6b08acc61ea5b7 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methotrimeprazine LC-ESI-QQ , positive-QTOF | splash10-0zfr-6920000000-dc5968beb0d112813d55 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methotrimeprazine LC-ESI-QQ , positive-QTOF | splash10-0a4i-9410000000-0d1f6734452bedc68d3f | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Methotrimeprazine LC-ESI-IT , positive-QTOF | splash10-0udi-0910000000-10fe32fa41981fcda652 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  10V, Positive-QTOF | splash10-004i-0469000000-698db513d68f8238a284 | 2016-06-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  20V, Positive-QTOF | splash10-0ue9-3983000000-0963d25ff0f442a1b819 | 2016-06-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  40V, Positive-QTOF | splash10-0pc3-9420000000-45332e32eecba186d700 | 2016-06-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  10V, Negative-QTOF | splash10-004i-0019000000-783dfd7af7ab08cc7337 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  20V, Negative-QTOF | splash10-00p0-0494000000-78a58d14f5fb19218ba8 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  40V, Negative-QTOF | splash10-002b-3960000000-d1127cf211de0694b952 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  10V, Positive-QTOF | splash10-004i-1109000000-34d749e2d87b91114995 | 2021-10-11 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  20V, Positive-QTOF | splash10-0a4i-9344000000-c57c58a83df0fed1de87 | 2021-10-11 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  40V, Positive-QTOF | splash10-0a4i-9010000000-9234afceb922b3e5fbf0 | 2021-10-11 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  10V, Negative-QTOF | splash10-004i-0019000000-30741f7748d9c6819aaa | 2021-10-12 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  20V, Negative-QTOF | splash10-004i-0095000000-978af20f8f7527c06c88 | 2021-10-12 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methotrimeprazine  40V, Negative-QTOF | splash10-0fb9-0190000000-60e894c19f034f06f29d | 2021-10-12 | Wishart Lab | View Spectrum | 
 | 
|---|